Histology-Derived Signatures Predict Recurrence Risk and Chemotherapy Benefit in Randomized Trials of Early Breast Cancer

PurposeTo test whether histology-derived gene-expression signatures from routine hematoxylin and eosin slides are prognostic for recurrence and predictive of chemotherapy benefit in early breast cancer. MethodsWe conducted a multi-cohort study including CALGB 9344 (anthracycline {+/-} paclitaxel), CALGB 9741 (standard vs dose-dense chemotherapy), a pooled Chicago real-world cohort, and the American Cancer Society (ACS) Cancer Prevention Studies-II and -3. Whole-slide images were processed with a previously described pipeline to generate 61 histology-derived signatures per patient. The primary endpoint was distant recurrence-free interval (DRFI), except in ACS, where breast cancer-specific survival was used. Secondary endpoints include distant recurrence-free survival (DRFS) and overall survival. The most prognostic signature in CALGB 9344, selected by Harrells C-index, was evaluated in additional cohorts. Signature-treatment interaction was assessed by likelihood-ratio tests. Multivariable Cox models incorporating age, tumor size, nodal status, estrogen/progesterone receptor status, and signature were fit in CALGB 9344 to improve risk stratification. ResultsA total of 7,170 patients were included across four cohorts. The top histology-derived signature in CALGB 9344 showed strong prognostic performance for 5-year DRFI (C-index 0.63) and performed well across validation cohorts (C-index 0.60, 0.70, and 0.62 in CALGB 9741, Chicago, and ACS, respectively). The strongest predictive signal for treatment benefit was observed for DRFS. High-risk cases identified by the signature demonstrated greater benefit from taxane in CALGB 9344 (adjusted hazard ratio [aHR] 0.76 for DRFS, 95% CI 0.66-0.88; interaction p=0.028), from dose-dense chemotherapy in CALGB 9741 (aHR 0.69, 95% CI 0.56-0.85; interaction p=0.039), and differential chemotherapy benefit in the Chicago cohort (aHR 0.84, 95% CI 0.59-1.21; interaction p=0.009). Combined clinical-histology models improved risk stratification and identified low-risk groups with a 2%-10% risk of distant recurrence or breast cancer death. ConclusionHistology-derived signatures from H&E images are broadly prognostic and, unlike clinical factors, may predict chemotherapy benefit. HighlightsO_LIHistology-derived H&E signatures consistently predicted recurrence risk across randomized trials and real-world cohorts. C_LIO_LIA single cutoff of a low-risk histology signature predicted taxane benefit and dose-dense chemotherapy benefit. C_LIO_LICombined clinical-histology models identified low-risk groups with 2%-10% risk of distant recurrence. C_LI